Sharma, Priya

52-year-old with HER2+ IIB breast cancer, excellent response on neoadjuvant THP (residual 0.8cm). Discuss de-escalation strategy — T-DM1 vs. continuation of HP given near-pCR. Factor in cardiac function (LVEF 58%).

52-year-old with HER2+ IIB breast cancer, excellent response on neoadjuvant THP (residual 0.8cm). Discuss de-escalation strategy — ado-trastuzumab emtansine (T-DM1) vs. continuation of HP given near-pCR. Factor in cardiac function (LVEF 58%) and patient preference for shorter treatment.

Optimal neoadjuvant anti-HER2 regimen — dual blockade (pertuzumab + trastuzumab) vs. T-DXd.

Post-neoadjuvant residual disease — T-DM1 vs. continuation of trastuzumab/pertuzumab.

De-escalation of chemotherapy backbone in early-stage HER2+ disease.

De-escalation of chemotherapy backbone in early-stage HER2+ disease.

Brain metastasis management with tucatinib-based regimen vs. SRS.

Optimal neoadjuvant anti-HER2 regimen — dual blockade (pertuzumab + trastuzumab) vs. T-DXd.

Post-neoadjuvant residual disease — T-DM1 vs. continuation of trastuzumab/pertuzumab.

Post-neoadjuvant residual disease — T-DM1 vs. continuation of trastuzumab/pertuzumab.

Post-neoadjuvant residual disease — T-DM1 vs. continuation of trastuzumab/pertuzumab.

De-escalation of chemotherapy backbone in early-stage HER2+ disease.

De-escalation of chemotherapy backbone in early-stage HER2+ disease.

De-escalation of chemotherapy backbone in early-stage HER2+ disease.

Brain metastasis management with tucatinib-based regimen vs. SRS.